We have now concluded our investigation for the complaint received.The batch record was reviewed and it could be confirmed that the products had progressed through a satisfactory release process which involved testing the product against the requirements of the finished product specification.There was also no issue identified during the manufacturing process that could have caused or contributed to the complaint problem.A complaints history review was carried out using the lot and part numbers provided, there have been no further complaints reported with this failure mode in the past three years.The device was used for treatment.It was reported that during treatment discolouration was identified on the dressing and surround skin site.The skin was then debrided as the discolouration was thought to be necrotised tissue.No images were provided of the reported issue.No samples were returned for evaluation.A clinical assessment was carried out.It was concluded; ¿no clinical/ medical documentation or pictures have been submitted to support this investigation.Without supporting clinical/medical documents, a thorough investigation cannot be performed.Should information become available this complaint can be re-assessed.¿ a risk management review was carried out.The risk files for this product captures local toxicity and local infection as harms related to using a discoloured dressing.No further actions are deemed necessary.Due to the properties of the material components of this dressing natural discolouration may occur.As stated in the ifu for this product ¿acticoat flex 3 may cause transient discolouration of the surrounding skin.The colour of the dressing may vary.This does not affect the performance of the dressing.¿ we have not been able to confirm a link between the event and description or identify a definitive root cause.No further actions by smith and nephew are deemed necessary at this stage.However, we will continue to monitor for any adverse trends relating to this product range.
|